THE SHORT ANSWER
Does Anthem Cover Zepbound?
Coverage Is Highly Variable
On most Anthem commercial drug lists, Zepbound is Tier 2 with prior authorization; on California DMHC lists the pen became non-formulary on October 1, 2026. Whether your plan covers weight-loss drugs at all depends on its benefit design, which your employer or plan sets.[1]
Anthem Blue Cross isn't a single insurance policy—it's a collection of different plans across states, employers, and product lines. Coverage depends on:
- Your specific Anthem entity (e.g., Anthem Blue Cross in California vs. Anthem Blue Cross Blue Shield in Virginia)
- Your employer's chosen benefits (self-funded employers can customize coverage)
- The pharmacy benefit manager (PBM) and its formulary (approved drug list) used by your plan
- Your plan type (commercial employer, health exchange, Medicaid, or Medicare Advantage)
Bottom line: You must check your exact formulary and benefit documents. Don't assume coverage based on "Anthem" alone—two Anthem members in the same state can have completely different coverage.
For a complete overview of getting Zepbound covered regardless of insurer, see our full coverage guide.
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get starteddenied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
"I found Honest Care online and was very impressed with the letter... the appeal worked!"
"My Appeal was approved the next day. Thank you Honest Care!"
PLANS, FORMULARIES & PBMS
How Anthem Decides Coverage
Understanding how Anthem makes coverage decisions helps you navigate the system:
Unlike Kaiser, Anthem Doesn't Employ Doctors
This is a key distinction. Kaiser Permanente is an integrated health system where doctors and insurance are part of the same organization. Anthem is a traditional insurer—coverage is driven by:
- Formulary tier placement (preferred, non-preferred, or excluded)
- Prior authorization criteria set by Anthem's pharmacy team
- Employer benefit decisions (what coverage the employer purchased)
This means your doctor wanting to prescribe Zepbound doesn't guarantee coverage. Anthem decides based on plan rules, not clinical preference.
Anthem Formulary Tiers Explained
| Tier | What It Means | Typical Zepbound Status |
|---|---|---|
| Preferred | Lowest cost-sharing, easiest access | Tier 2 (with PA) on most Anthem commercial drug lists in 2026[1] |
| Non-Preferred | Higher cost-sharing; may require PA | Tier 3 on some lists (for example, Anthem's California CDI lists)[1] |
| Excluded | Not on the drug list; a formulary exception or a plan change may be the only way to get it covered | Plans can exclude weight-loss drugs through their benefit design; the Zepbound pen is non-formulary on Anthem's California DMHC lists since 10/1/2026[1] |
How to Check Your Anthem Formulary
- Log into your Anthem member portal at anthem.com
- Go to "Pharmacy" then "Drug List" or "Formulary"
- Search for "Zepbound" or "tirzepatide"
- Note the tier, PA requirements, and quantity limits
- Download your plan's full formulary PDF for complete details
Can't find it? Call the number on your Anthem ID card and request your formulary in writing.
Call Script for Anthem
"Hi, I'm calling to check coverage for a prescription medication. My member ID is [NUMBER]. I need to know:
- Is Zepbound (tirzepatide) covered on my plan's formulary for weight management?
- What tier is it on?
- Is prior authorization required?
- What are the coverage criteria—BMI, comorbidities (related health conditions), step therapy?
- Can you send me the coverage policy in writing?"
WHAT TO EXPECT BY PLAN TYPE
Anthem's 2026 Zepbound Coverage
Here's the realistic coverage landscape for Anthem members in 2026:
Coverage by Plan Type and Region
| Plan Type | 2026 Status | PA/Step Therapy | Notes |
|---|---|---|---|
| Commercial HMO/PPO/POS | Varies | Yes, if covered | Tier 2 with PA on most 2026 commercial drug lists, if your plan covers weight-loss drugs[1] |
| Commercial Employer | Varies by employer | Yes, if covered | Self-funded employers can customize; ask HR |
| Fully-Insured Large Group | Varies | Yes, if covered | Depends on the plan's benefit design (some other Blue plans, such as BCBS Michigan, ended fully insured large-group coverage on 1/1/2025)[2] |
| Health Exchange (ACA) | Varies | Yes, if covered | Check your plan's drug list; weight-loss drugs may be excluded by the plan's benefit design |
| Managed Medicaid HMO | Varies by state | Yes | Follows your state's Medicaid rules; 13 states (as of January 2026) covered GLP-1s for obesity |
| Medicare Advantage (MA-PD) | Not by the plan; Medicare GLP-1 Bridge: $50 per monthly fill (with conditions) | N/A | Basic Medicare Part D coverage excludes drugs used for weight loss by statute; the Bridge, which runs outside Part D, covers the Zepbound KwikPen only (not vials or single-dose pens) if you meet CMS's criteria and your prescriber gets prior authorization |
| Medicare PDP | Not by the plan; Medicare GLP-1 Bridge: $50 per monthly fill (with conditions) | N/A | Same federal exclusion applies; PDP members who meet CMS's criteria can use the Bridge (Zepbound KwikPen only; prior authorization required) |
2025 GLP-1 Coverage Rollbacks
Major Coverage Changes in 2025-2026
Several Blue Cross/Blue Shield plans and state programs have tightened or ended GLP-1 weight-loss coverage due to cost concerns:
- California Medi-Cal (including Anthem Blue Cross Medi-Cal members): Medi-Cal stopped covering GLP-1s for weight loss on January 1, 2026; Zepbound can still be approved for OSA, and Wegovy for cardiovascular risk or MASH, with prior authorization[14]
- Blue Cross Blue Shield of Michigan: BCBS Michigan ended coverage for fully insured large-group plans on January 1, 2025[2]
- Blue Shield of California: Since January 1, 2025 (or plan renewal), some Blue Shield of California plans cover weight-loss drugs only for Class III obesity (BMI 40+), with a weight-loss program[3]
- BCBS of Massachusetts: Blue Cross Blue Shield of Massachusetts excludes Saxenda, Wegovy and Zepbound from January 1, 2026 (for obesity)[4]
None of these are Anthem commercial changes, but similar cost pressures apply across insurers—check your specific Anthem plan.
State-by-State Anthem Coverage
Anthem operates under different names in different states. Here's what we know:
| State | Anthem Entity | Coverage Notes |
|---|---|---|
| California | Anthem Blue Cross | Medi-Cal: Weight loss coverage ended 1/1/2026; OSA can still be approved[14]. Commercial: on Anthem's California DMHC drug lists the Zepbound pen became non-formulary on 10/1/2026 (the KwikPen moved to Tier 2)[1] |
| Virginia | Anthem BCBS | Coverage varies by plan; PA required for GLP-1s |
| Ohio | Anthem BCBS | Coverage varies by plan; PA required on Anthem drug lists |
| Georgia | Anthem BCBS | Coverage varies by plan type |
| Indiana | Anthem BCBS | PA required on Anthem drug lists; verify your specific plan |
| New York | Anthem BCBS | State-specific drug list available[7] |
This table reflects general trends—coverage policies change frequently. Always verify with your specific Anthem plan.
ANTHEM CRITERIA FOR ZEPBOUND
Prior Authorization Requirements
When Anthem does cover Zepbound, its drug lists show prior authorization as required.[1] Anthem's own criteria sit in its online drug-list search rather than a public document we could review, so ask for them in writing. Criteria commonly used by major insurers:
- BMI ≥30 (or ≥27 with hypertension, type 2 diabetes, sleep apnea, etc.)
- 3-6 months documented lifestyle efforts (diet and exercise in your medical record)
- No concurrent GLP-1 use (can't take Ozempic, Wegovy at same time)
- Step therapy: Some plans require trying other meds first
- Renewal: Must show ≥5% weight loss to continue coverage
For complete documentation checklists and PA preparation: Zepbound Prior Authorization Guide →
denied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
CLINICAL VS. COVERAGE DECISIONS
Why Your Doctor's Answer May Differ
"My Doctor Says Yes, Anthem Says No"
Your doctor determining Zepbound is "medically appropriate" doesn't mean Anthem will pay for it. These are separate decisions made by different people with different criteria.
Here's why this disconnect happens:
| Your Doctor's Perspective | Anthem's Perspective |
|---|---|
| "Is this clinically appropriate for this patient?" | "Does this meet our documented criteria?" |
| Based on clinical judgment and guidelines | Based on formulary rules and policy documents |
| Considers individual patient circumstances | Applies standardized criteria to all members |
| Goal: What's best for this patient? | Goal: What meets documented criteria? |
What To Do About It
- Get specific criteria from Anthem—request the exact PA requirements in writing
- Work with your doctor to ensure documentation meets Anthem's standards, not just clinical standards
- Document everything—Anthem reviewers only see what's in the paperwork
- Don't just resubmit—if denied, address the specific denial reason with new documentation
Ask Your Doctor For Detailed Notes
A brief PA note won't succeed. Your doctor needs to include:
- Specific measurements (current BMI, weight history)
- ICD-10 codes for all qualifying conditions
- Details of failed lifestyle interventions
- Impact of obesity on daily functioning
- Why Zepbound specifically (not just "any GLP-1")
YOUR OPTIONS
If Anthem Denies Zepbound
Appeals Can Work
65%+ of appealed prior authorization denials are overturned with strong documentation. Even for formulary exclusions, exception requests can succeed.[8]
Common Anthem denial reasons for Zepbound:
- Formulary exclusion / excluded benefit → Formulary Exclusion Guide
- Medical necessity not met → Medical Necessity Guide
- Step therapy required → Step Therapy Guide
Anthem Appeal Basics
- Deadline: 180 days from denial to file internal appeal, unless your plan documents say otherwise (check your letter)
- Tip: Ask your doctor for a peer-to-peer review with Anthem's medical director
- "Excluded benefit"? Consider the OSA pathway or self-pay options
For complete appeal strategies: Zepbound Appeals Guide → | External Review Process
ALTERNATIVES
If Anthem Won't Cover Zepbound
Sleep Apnea (OSA) Pathway
Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Some plans that exclude "weight loss" may still cover this use, so ask Anthem whether yours does. See our complete OSA coverage guide →
Other options if coverage isn't available:
- Self-pay via LillyDirect: Vials and KwikPens at $299–$449/month by dose[11] → Zepbound Cost Guide
- TrumpRx.gov: TrumpRx lists the manufacturers’ own self-pay prices (not a separate, cheaper price); for Zepbound that's the LillyDirect price above (launched February 5, 2026)[15]
- Foundayo: Eli Lilly's oral GLP-1 tablet (FDA approved April 1, 2026)—no injections, may have different coverage
- Compare medications: Wegovy, Mounjaro & more → Alternatives Guide
- Switch plans: Check other insurers during open enrollment
WHAT'S CHANGING
2026 Outlook
Major developments are reshaping GLP-1 access in 2026. Here's what Anthem members should know:
TrumpRx Program Now Live
The Trump administration launched TrumpRx.gov on February 5, 2026. TrumpRx lists the manufacturers’ own self-pay prices (not a separate, cheaper price):[15]
- Current pricing: Zepbound vials at the LillyDirect self-pay price ($299–$449/month); orders go through LillyDirect
- Medicare: separately, the Medicare GLP-1 Bridge charges eligible Part D enrollees $50 per monthly fill; participating manufacturers provide Bridge drugs at a net program price of $245 per monthly supply (not what you pay)
- How to access: Visit TrumpRx.gov
This provides an alternative for Anthem members denied coverage.
CMS BALANCE Model & Medicare Changes
CMS announced the voluntary BALANCE Model on December 23, 2025, to expand Medicare/Medicaid GLP-1 access:[16]
- Medicare GLP-1 Bridge (live July 1, 2026 – December 31, 2027): $50 per monthly fill for beneficiaries with eligible Part D coverage who meet CMS's criteria and get prior authorization; covers the Zepbound KwikPen only (not vials or single-dose pens)
- Medicaid: Voluntary for states, which can join between May 2026 and January 1, 2027; no participating state has been confirmed
- Medicare Part D: BALANCE is Delayed, with no new start date
Anthem Medicare Advantage members with drug coverage may be able to use the Bridge if they meet CMS's criteria: Part D plans and pharmacies don’t opt in, and you don’t enroll separately; your prescriber must get prior authorization.
Anthem-Specific Changes to Watch
- CarelonRx formulary updates: Anthem's PBM (CarelonRx, formerly IngenioRx) may adjust tier placement and PA requirements—verify your 2026 formulary
- California Medi-Cal: Weight loss coverage ended 1/1/2026; the OSA use can still be approved with prior authorization[14]
- State variation continues: Anthem drug lists differ by state and plan (for example, California); check your specific plan
- More rollbacks possible: Following BCBS Michigan, Massachusetts, and California Medi-Cal cuts, some Anthem affiliates may tighten coverage
For Medicare and self-pay updates: Medicare Coverage Guide | Zepbound Cost Guide
ANTHEM & GLP-1 MEDICATIONS
Frequently Asked Questions
It depends on your specific plan. On most Anthem commercial drug lists, Zepbound is Tier 2 with prior authorization; on California DMHC lists the pen became non-formulary on October 1, 2026. Whether your plan covers weight-loss drugs at all depends on its benefit design. You must check your exact formulary—two Anthem members in the same state can have completely different coverage.
Zepbound is only FDA-approved for weight loss and sleep apnea—not diabetes. For diabetes, the same active ingredient (tirzepatide) is sold as Mounjaro, the version approved for type 2 diabetes. If you have type 2 diabetes, ask your doctor about Mounjaro instead.
Anthem doesn't publish its Zepbound criteria as a public document. Published criteria at other insurers, such as Aetna's, use thresholds that match the FDA label: BMI ≥30 (obesity) or BMI ≥27 with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea. Some plans have stricter requirements. Request your plan's specific PA criteria in writing.
Not across the board. On most Anthem commercial drug lists, Zepbound is Tier 2 with prior authorization; on California DMHC lists the pen became non-formulary on October 1, 2026. Separately, California Medi-Cal (which covers drugs for Anthem Medi-Cal members through Medi-Cal Rx) ended weight-loss coverage on 1/1/2026. Other Blue companies cut coverage for some members: BCBS Michigan for fully insured large groups on 1/1/2025, and BCBS Massachusetts from 1/1/2026. Check your specific plan, as commercial coverage varies by employer.
Yes. Formulary and coverage policies can change at plan renewal (typically January 1 or your employer's renewal date). If you're currently covered, you may receive notice of formulary changes before renewal. Always re-verify coverage at the start of each plan year.
Some states have proposed laws requiring coverage of obesity treatments, but these mandates vary and may not apply to all plan types (particularly self-funded employer plans regulated under federal ERISA law). State mandates apply to fully insured plans, not self-funded ones.
Anthem's approval lengths aren't published in a public document. For comparison, Aetna's published criteria give an initial approval of 8 months and 12 months renewals with at least 5% weight loss; other insurers set their own lengths. Check your PA approval letter for your specific dates and requirements.
Potentially yes. Zepbound received FDA approval for moderate-to-severe obstructive sleep apnea (OSA) in December 2024. Some plans that exclude weight loss coverage may cover Zepbound under the OSA indication. Published OSA criteria at insurers such as Aetna and UnitedHealthcare require BMI ≥30 and a sleep study showing moderate-to-severe OSA (AHI ≥15 at Aetna; over 15 at UnitedHealthcare).
YOUR PATH FORWARD
What's Next
Zepbound Coverage: Other Major Insurers
See how other insurers compare on Zepbound coverage:
- Blue Cross Blue Shield — Each Blue company (Anthem is one) sets its own rules; some dropped weight-loss coverage
- UnitedHealthcare — Depends on your employer’s plan; PA required where covered
- Cigna — Depends on your employer's plan; PA required (Cigna policy IP0816)
- Aetna — Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize) (Aetna's PBM); customized plans vary
- Kaiser Permanente — Depends on your region and plan
References
- Anthem. (2026). "Formulary Update" (quarterly commercial drug list changes; Zepbound standard pen and KwikPen entries, effective 8/1/2026 and 10/1/2026). anthem.com
- Blue Cross Blue Shield of Michigan. (2024). "Changes coming for select weight loss drugs for some commercial members." Provider Alert. bcbsm.com
- Blue Shield of California. (2024). "Weight Loss Drug Exclusion Fact Sheet." blueshieldca.com
- Blue Cross Blue Shield of Massachusetts. (May 29, 2025). "GLP-1 medications for obesity: coverage update." bluecrossma.com
- Anthem Blue Cross California. (2025). "Prior Authorization Requirements." providers.anthem.com
- Anthem Provider News Ohio. (2025). "Important update: required documentation for select ePA requests." Confirms GLP-1 medications require attached documentation for ePA. providernews.anthem.com
- Anthem. (2025). "New York Drug List." anthem.com
- American Medical Association. (2024). "Over 80% of Prior Auth Appeals Succeed—Why Aren't There More?" ama-assn.org; U.S. GAO. (2011). "Private Health Insurance: Data on Application and Coverage Denials." GAO-11-268. gao.gov
- Jastreboff AM, et al. (2022). "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. SURMOUNT-1 trial. PubMed
- U.S. Government Accountability Office. (2011). "Private Health Insurance: Data on Application and Coverage Denials." GAO-11-268. 39-59% of appeals reversed; ~40% of external reviews overturned. gao.gov
- Eli Lilly. "LillyDirect: Zepbound self-pay pricing." lilly.com/lillydirect/zepbound
- Anthem. (2025). "Drug List | Formulary." anthem.com
- Anthem. (2025). "Medical Policies & Clinical UM Guidelines." anthem.com
- California Department of Health Care Services. (November 14, 2025). "Medi-Cal Rx Contract Drugs List Update: GLP-1 Coverage Changes Effective January 1, 2026." Wegovy, Zepbound, and Saxenda removed from CDL for weight loss indications; other approved uses (e.g., Zepbound for OSA) can still be approved with PA. medi-calrx.dhcs.ca.gov
- White House. (November 6, 2025). "TrumpRx: Expanding Access to Weight Loss Medications." Announced Medicare GLP-1 pricing (participating manufacturers provide Bridge drugs at a net program price of $245 per monthly supply; patients pay $50) and the TrumpRx direct-to-consumer platform, which lists manufacturers' own self-pay prices. Partnership with Eli Lilly and Novo Nordisk. whitehouse.gov
- Centers for Medicare & Medicaid Services. (December 23, 2025). "CMS Announces BALANCE Model for GLP-1 Access." Medicaid track voluntary for states; Medicare Part D track later delayed by CMS with no new start date; the separate Medicare GLP-1 Bridge runs July 1, 2026 – December 31, 2027 ($50/month). cms.gov
Last updated October 6, 2026 · Key facts verified October 5, 2026 · Full page reviewed October 5, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.